Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ESMO 2019 Integration of veliparib in the treatment of gynaecological cancer

At this ESMO congress, prof. Robert Coleman presented data on the VELIA/GOG-3005 trial, which investigated the effectivity and tolerability of veliparib on gynaecological tumors. In this interview, he shares the main findings with regard to progression-free survival and toxicity.

  • Sponsors

    This program is editorially independent and is financially supported by: